Formiga F, Camafort M, Carrasco Sánchez FJ. Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. Rev Clin Esp. 2020 Mar;220(2):135–8.
Article
CAS
PubMed
Google Scholar
Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541–9.
Article
PubMed Central
PubMed
Google Scholar
Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1?9 million people. Lancet. 2015;26(385 Suppl 1):86.
Article
Google Scholar
Avogaro A, Azzolina D, Fadini GP, Baldi I. Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. J Endocrinol Invest. 2021;44(4):745–53.
Article
CAS
PubMed
Google Scholar
Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614–9.
Article
CAS
PubMed
Google Scholar
From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9.
Article
PubMed
Google Scholar
McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(5):602–11.
Article
PubMed
Google Scholar
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–77.
Article
PubMed
Google Scholar
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660–71.
Article
CAS
PubMed Central
PubMed
Google Scholar
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–87.
Article
PubMed
Google Scholar
Gøtzsche O, Darwish A, Gøtzsche L, Hansen LP, Sørensen KE. Incipient cardiomyopathy in young insulin-dependent diabetic patients: a seven-year prospective Doppler echocardiographic study. Diabet Med. 1996;13(9):834–40.
Article
PubMed
Google Scholar
Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A, et al. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3(11):876–85.
Article
PubMed
Google Scholar
Evangelista I, Nuti R, Picchioni T, Dotta F, PalazzuoliInt A. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. J Mol Sci. 2019;20(13):3264.
Article
CAS
Google Scholar
Borghetti G, von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514.
Article
PubMed Central
PubMed
Google Scholar
Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585–607.
Article
PubMed Central
PubMed
Google Scholar
Spillmann F, Linthout SV, Tschöpe C. Cardiac effects of HDL and its components on diabetic cardiomyopathy. Endocr Metab Immune Disord Drug Targets. 2012;12(2):132–47.
Article
CAS
PubMed
Google Scholar
Xu X, Luo Z, He Y, Shan J, Guo J, Li J. Application of untargeted lipidomics based on UHPLC-high resolution tandem MS analysis to profile the lipid metabolic disturbances in the heart of diabetic cardiomyopathy mice. J Pharm Biomed Anal. 2020;190:113525.
Article
CAS
PubMed
Google Scholar
Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19(6):27.
Article
PubMed
Google Scholar
Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324–40.
Article
PubMed
Google Scholar
Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62(7):1020–31.
Article
CAS
PubMed
Google Scholar
Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3(5):e001221.
Article
PubMed Central
PubMed
Google Scholar
Ritchie RH, Zerenturk EJ, Prakoso D, Calkin AC. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. J Mol Endocrinol. 2017;58(4):R225–40.
Article
CAS
PubMed
Google Scholar
Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. JACC. 2006;47(3):598–604.
Article
CAS
PubMed
Google Scholar
Varbo A, Nordestgaard BG. Remnant cholesterol and ischemic heart disease. Curr Opin Lipidol. 2014;25(4):266–73.
Article
CAS
PubMed
Google Scholar
Jensen MT, Sogaard P, Andersen HU, Bech J, Hansen TF, Galatius S, et al. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia. 2014;57(4):672–80.
Article
CAS
PubMed
Google Scholar
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.
Article
PubMed
Google Scholar
Mallol R, Amigó N, Rodríguez MA, Heras M, Vinaixa M, Plana N, et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res. 2015;56(3):737–46.
Article
CAS
PubMed Central
PubMed
Google Scholar
Fuertes-Martín R, Taverner D, Vallvé JC, Paredes S, Masana L, Correig X, et al. Characterization of 1H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory Patterns in Rheumatoid Arthritis. J Proteome Res. 2018;17(11):3730–9.
Article
PubMed
Google Scholar
Fuertes-Martín R, Moncayo S, Insenser M, Martínez-García MA, Luque-Ramírez M, Amigó Grau N, et al. Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS). J Proteome Res. 2019;18(11):4038–4045.
Bro R, Smilde AK. Principal component analysis. Anal Methods. 2014;6:2812–31.
Article
CAS
Google Scholar
Lee LC, Liong CY, Jemain AA. Partial least squares-discriminant analysis (PLS-DA) for classification of high-dimensional (HD) data: a review of contemporary practice strategies and knowledge gaps. Analyst. 2018;143(15):3526–39.
Article
CAS
PubMed
Google Scholar
Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 2018;114(1):2.
Article
PubMed Central
PubMed
Google Scholar
Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. Herz. 2019:96–106.
Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714–23.
Article
CAS
PubMed
Google Scholar
Fuertes-Martín R, Correig X, Vallvé JC, Amigó N. Title: human serum/plasma glycoprotein analysis by 1H-NMR, an emerging method of inflammatory assessment. J Clin Med. 2020;9(2):354.
Article
PubMed Central
PubMed
Google Scholar
Ballout RA, Remaley AT. GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. J Lab Precis Med. 2020;5:17.
Article
PubMed Central
PubMed
Google Scholar
Rodríguez-Carrio J, Alperi-López M, López P, Pérez-Álvarez AI, Gil-Serret M, Amigó N, et al. GlycA levels during the earliest stages of rheumatoid arthritis: potential use as a biomarker of subclinical cardiovascular disease. J Clin Med. 2020;9(8):2472.
Article
PubMed Central
PubMed
Google Scholar
Carmona-Maurici J, Amigó N, Cuello E, Bermúdez M, Baena-Fustegueras JA, Peinado-Onsurbe J. Bariatric surgery decreases oxidative stress and protein glycosylation in patients with morbid obesity. Eur J Clin Invest. 2020;50(11):e13320.
Article
CAS
PubMed
Google Scholar
Mehta NN, Dey AK, Maddineni R, Kraus WE, Huffman KM. GlycA measured by NMR spectroscopy is associated with disease activity and cardiovascular disease risk in chronic inflammatory diseases. Am J Prev Cardiol. 2020;4:100120.
Article
PubMed Central
PubMed
Google Scholar
Connelly MA, Otvos JD, Shalaurova I, Playford MP, Mehta NN. GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. J Transl Med. 2017;15:219.
Article
PubMed Central
PubMed
Google Scholar
Moncayo S, Insenser M, Martínez-García MA, Fuertes-Martín R, Amigó-Grau N, Álvarez-Blasco F, et al. Acute-phase glycoprotein profile responses to different oral macronutrient challenges: Influence of sex, functional hyperandrogenism and obesity. Clin Nutr. 2021;40(3):1241–6.
Article
CAS
PubMed
Google Scholar
Jang S, Ogunmoroti O, Ndumele CE, Zhao D, Rao VN, Fashanu OE, et al. Association of the novel inflammatory marker GlycA and incident heart failure and its subtypes of preserved and reduced ejection fraction: the multi-ethnic study of atherosclerosis. Circ Heart Fail. 2020;13(8):e007067.
Article
CAS
PubMed Central
PubMed
Google Scholar
Llauradó G, Amigó N, Cano A, Ballesta S, Albert L, Mazarico I, et al. Specific nuclear magnetic resonance lipoprotein subclass profiles and central arterial stiffness in Type 1 diabetes mellitus: a case control study. J Clin Med. 2019;8(11):1875.
Article
PubMed Central
PubMed
Google Scholar
Amor AJ, Vinagre I, Valverde M, Urquizu X, Meler E, López E, et al. Nuclear magnetic resonance lipoproteins are associated with carotid atherosclerosis in type 1 diabetes and pre-eclampsia. Diabetes Metab Res Rev. 2021;37(1):e3362.
Article
CAS
PubMed
Google Scholar
Varbo A, Nordestgaard BG. Nonfasting triglycerides, low-density lipoprotein cholesterol, and heart failure risk: two cohort studies of 113 554 individuals. Arterioscler Thromb Vasc Biol. 2018;38(2):464–72.
Article
CAS
PubMed
Google Scholar
Nakajima K, Tokita Y, Tanaka A, Takahashi S. The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins. Clin Chim Acta. 2019;495:382–93.
Article
CAS
PubMed
Google Scholar
Perman JC, Boström P, Lindbom M, Lidberg U, StÅhlman M, Hägg D, et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest. 2011;121(7):2625–40.
Article
CAS
PubMed Central
PubMed
Google Scholar
Lee HC, Lin YH. The Pathogenic Role of Very Low Density Lipoprotein on Atrial Remodeling in the Metabolic Syndrome. Int J Mol Sci. 2020;21(3):891.
Article
CAS
PubMed Central
PubMed
Google Scholar
Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol. 2017;5(10):799–807.
Article
PubMed
Google Scholar